Michelle Haber Selected Research

multidrug resistance-associated protein 1

1/2022	GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators.
12/2021	Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition.
10/2019	MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells.
1/2016	ABC transporters as mediators of drug resistance and contributors to cancer cell biology.
9/2014	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).
10/2009	Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
8/2009	Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.
12/2007	Role of the MRP1/ABCC1 multidrug transporter protein in cancer.
4/2006	Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
10/2005	The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michelle Haber Research Topics

Disease

92	Neoplasms (Cancer) 04/2022 - 09/2003
68	Neuroblastoma 01/2022 - 03/2003
16	Carcinogenesis 01/2021 - 07/2003
15	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 06/2002
14	Leukemia 01/2022 - 06/2002
9	Breast Neoplasms (Breast Cancer) 12/2021 - 07/2003
6	Residual Neoplasm 08/2015 - 02/2003
5	Brain Neoplasms (Brain Tumor) 12/2021 - 06/2015
4	Ovarian Neoplasms (Ovarian Cancer) 10/2019 - 05/2014
3	Ovarian Epithelial Carcinoma 04/2022 - 07/2014
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 11/2014
3	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 01/2020
3	Lung Neoplasms (Lung Cancer) 10/2019 - 05/2009
2	Glioma (Gliomas) 12/2021 - 01/2018
2	Diffuse Intrinsic Pontine Glioma 12/2021 - 01/2021
2	Sarcoma (Soft Tissue Sarcoma) 11/2021 - 09/2021
2	Hypoxia (Hypoxemia) 01/2020 - 10/2007
2	Neoplasm Metastasis (Metastasis) 08/2016 - 04/2014
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2013 - 02/2012
1	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2022
1	Drug-Related Side Effects and Adverse Reactions 12/2021
1	Rheumatoid Arthritis 01/2021

Drug/Important Bio-Agent (IBA)

28	Pharmaceutical PreparationsIBA 01/2022 - 07/2002
27	Proteins (Proteins, Gene)FDA Link 04/2022 - 03/2003
12	multidrug resistance-associated protein 1IBA 01/2022 - 01/2004
11	ATP-Binding Cassette Transporters (ABC Transporters)IBA 12/2021 - 01/2010
9	EnzymesIBA 04/2021 - 09/2007
9	Oncogene Proteins (Oncogene Protein)IBA 04/2021 - 02/2010
8	Small Interfering RNA (siRNA)IBA 04/2022 - 10/2007
8	Histone Deacetylase InhibitorsIBA 01/2022 - 06/2006
8	Adenosine Triphosphate (ATP)IBA 10/2020 - 09/2008
7	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2016
7	PolyaminesIBA 12/2021 - 12/2008
7	RetinoidsIBA 08/2015 - 03/2003
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2014
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 02/2012
6	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 06/2002
5	CBLC137IBA 01/2022 - 11/2015
5	Histone Deacetylases (Histone Deacetylase)IBA 01/2022 - 11/2007
5	ChromatinIBA 01/2022 - 05/2009
5	Biological ProductsIBA 10/2020 - 06/2002
5	Eflornithine (Ornidyl)FDA Link 01/2019 - 12/2008
4	Glutathione (Reduced Glutathione)IBA 01/2022 - 01/2016
4	Drug CombinationsIBA 01/2022 - 01/2020
4	Messenger RNA (mRNA)IBA 10/2020 - 01/2016
4	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 10/2019 - 05/2011
4	Indicators and Reagents (Reagents)IBA 01/2018 - 02/2003
4	Folic Acid (Vitamin M)FDA LinkGeneric 06/2015 - 06/2010
3	PanobinostatIBA 01/2022 - 01/2019
3	N-Myc Proto-Oncogene ProteinIBA 11/2019 - 06/2011
3	Long Noncoding RNAIBA 11/2019 - 04/2014
3	CationsIBA 01/2019 - 01/2012
2	CholesterolIBA 04/2022 - 07/2014
2	taxaneIBA 12/2021 - 02/2016
2	dipinacoline glutamateIBA 12/2021 - 01/2021
2	Complement System Proteins (Complement)IBA 12/2021 - 07/2015
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2021 - 12/2020
2	Immune Checkpoint InhibitorsIBA 11/2021 - 01/2020
2	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 11/2021 - 06/2007
2	Ornithine Decarboxylase (Decarboxylase, Ornithine)IBA 04/2021 - 01/2019
2	Phosphotransferases (Kinase)IBA 12/2020 - 01/2019
2	Copper Transporter 1IBA 10/2020 - 01/2016
2	CopperIBA 10/2020 - 01/2016
2	OT-82IBA 01/2020 - 01/2020
2	NAD (NADH)IBA 01/2020 - 01/2020
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2020 - 09/2008
2	Carrier Proteins (Binding Protein)IBA 11/2019 - 11/2009
2	Caspase 2IBA 01/2019 - 05/2013
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2017 - 04/2005
2	Tripartite Motif ProteinsIBA 05/2016 - 02/2012
2	Conditioned Culture MediaIBA 02/2016 - 11/2009
2	Methotrexate (Mexate)FDA LinkGeneric 06/2015 - 07/2002
2	LipidsIBA 01/2015 - 07/2014
2	reversanIBA 08/2011 - 08/2009
2	Protein Isoforms (Isoforms)IBA 02/2010 - 10/2009
2	Protein Glutamine gamma Glutamyltransferase 2IBA 02/2010 - 11/2007
2	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2009 - 07/2002
2	Antisense OligonucleotidesIBA 07/2009 - 09/2003
2	retinoic acid receptor betaIBA 05/2009 - 06/2006
2	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 05/2009 - 03/2003
2	DNA (Deoxyribonucleic Acid)IBA 09/2007 - 07/2003
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 06/2006 - 03/2003
1	Transcription Activator-Like Effector NucleasesIBA 04/2022
1	Antigen Receptors (Antigen Receptor)IBA 04/2022
1	Membrane Transport Proteins (Biological Pump)IBA 01/2022
1	ruxolitinibIBA 11/2021
1	Chimeric Antigen ReceptorsIBA 09/2021
1	Quinacrine (Mepacrine)IBA 01/2021
1	PolyubiquitinIBA 01/2021
1	Azacitidine (5 Azacytidine)FDA Link 01/2021
1	Auranofin (Ridaura)FDA Link 01/2021
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2021

Therapy/Procedure

43	Therapeutics 01/2022 - 02/2003
24	Drug Therapy (Chemotherapy) 01/2022 - 02/2003
6	Immunotherapy 01/2022 - 07/2015
4	Radiotherapy 11/2021 - 07/2009
3	Precision Medicine 01/2022 - 01/2018
2	Combined Modality Therapy 01/2022 - 01/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 04/2022
1	Heterologous Transplantation (Xenotransplantation) 01/2022